Erasca (ERAS) Competitors $1.52 -0.02 (-1.30%) Closing price 04:00 PM EasternExtended Trading$1.52 -0.01 (-0.33%) As of 05:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ERAS vs. EVO, OCUL, VERA, ETNB, BHVN, ANIP, MESO, EWTX, JANX, and TVTXShould you be buying Erasca stock or one of its competitors? The main competitors of Erasca include Evotec (EVO), Ocular Therapeutix (OCUL), Vera Therapeutics (VERA), 89BIO (ETNB), Biohaven (BHVN), ANI Pharmaceuticals (ANIP), Mesoblast (MESO), Edgewise Therapeutics (EWTX), Janux Therapeutics (JANX), and Travere Therapeutics (TVTX). These companies are all part of the "pharmaceutical products" industry. Erasca vs. Its Competitors Evotec Ocular Therapeutix Vera Therapeutics 89BIO Biohaven ANI Pharmaceuticals Mesoblast Edgewise Therapeutics Janux Therapeutics Travere Therapeutics Evotec (NASDAQ:EVO) and Erasca (NASDAQ:ERAS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings. Which has preferable valuation and earnings, EVO or ERAS? Erasca has lower revenue, but higher earnings than Evotec. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEvotec$862.40M1.72-$212.18MN/AN/AErascaN/AN/A-$161.65M-$0.62-2.45 Do institutionals and insiders believe in EVO or ERAS? 5.8% of Evotec shares are owned by institutional investors. Comparatively, 67.8% of Erasca shares are owned by institutional investors. 1.0% of Evotec shares are owned by company insiders. Comparatively, 14.4% of Erasca shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is EVO or ERAS more profitable? Erasca has a net margin of 0.00% compared to Evotec's net margin of -26.34%. Evotec's return on equity of -21.51% beat Erasca's return on equity.Company Net Margins Return on Equity Return on Assets Evotec-26.34% -21.51% -10.54% Erasca N/A -36.56%-31.08% Do analysts rate EVO or ERAS? Evotec presently has a consensus price target of $5.93, indicating a potential upside of 42.29%. Erasca has a consensus price target of $4.57, indicating a potential upside of 200.75%. Given Erasca's stronger consensus rating and higher probable upside, analysts plainly believe Erasca is more favorable than Evotec.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evotec 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40Erasca 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, EVO or ERAS? Evotec has a beta of 1.66, suggesting that its stock price is 66% more volatile than the S&P 500. Comparatively, Erasca has a beta of 1.05, suggesting that its stock price is 5% more volatile than the S&P 500. Does the media refer more to EVO or ERAS? In the previous week, Evotec and Evotec both had 2 articles in the media. Erasca's average media sentiment score of 1.02 beat Evotec's score of 0.55 indicating that Erasca is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evotec 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Erasca 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryErasca beats Evotec on 8 of the 12 factors compared between the two stocks. Get Erasca News Delivered to You Automatically Sign up to receive the latest news and ratings for ERAS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ERAS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ERAS vs. The Competition Export to ExcelMetricErascaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$436.26M$2.96B$5.56B$9.04BDividend YieldN/A2.42%5.25%4.03%P/E Ratio-2.4521.1127.1820.14Price / SalesN/A284.26439.56137.26Price / CashN/A42.7337.5058.41Price / Book1.017.748.085.60Net Income-$161.65M-$54.96M$3.16B$248.43M7 Day Performance10.14%6.04%3.77%5.15%1 Month Performance-5.59%4.47%3.90%7.62%1 Year Performance-43.28%6.12%34.22%21.56% Erasca Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ERASErasca2.6125 of 5 stars$1.52-1.3%$4.57+200.8%-43.2%$436.26MN/A-2.45120News CoveragePositive NewsEVOEvotec1.5099 of 5 stars$4.20+1.0%$5.93+41.3%-18.9%$1.48B$862.40M0.004,827News CoverageOCULOcular Therapeutix3.9064 of 5 stars$9.28+0.7%$17.33+86.8%+66.8%$1.47B$63.72M-8.07230VERAVera Therapeutics3.3496 of 5 stars$23.56+4.0%$65.00+175.9%-30.9%$1.44BN/A-7.8540ETNB89BIO1.5893 of 5 stars$9.82-0.4%$26.43+169.1%+31.2%$1.44BN/A-2.9140News CoverageBHVNBiohaven3.4243 of 5 stars$14.11+0.1%$58.46+314.3%-59.0%$1.44BN/A-1.51239Gap UpANIPANI Pharmaceuticals4.1558 of 5 stars$65.25-0.4%$80.13+22.8%+6.5%$1.42B$614.38M-51.38600Positive NewsAnalyst ForecastMESOMesoblast1.9826 of 5 stars$10.89-0.3%$18.00+65.3%+38.4%$1.40B$5.90M0.0080Positive NewsEWTXEdgewise Therapeutics2.679 of 5 stars$13.11-0.5%$40.00+205.1%-38.3%$1.39BN/A-8.4660JANXJanux Therapeutics1.613 of 5 stars$23.10-0.2%$95.25+312.3%-38.8%$1.37B$10.59M-16.9930TVTXTravere Therapeutics3.2315 of 5 stars$14.80+0.2%$32.14+117.2%+72.1%$1.31B$233.18M-5.27460 Related Companies and Tools Related Companies Evotec Alternatives Ocular Therapeutix Alternatives Vera Therapeutics Alternatives 89BIO Alternatives Biohaven Alternatives ANI Pharmaceuticals Alternatives Mesoblast Alternatives Edgewise Therapeutics Alternatives Janux Therapeutics Alternatives Travere Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ERAS) was last updated on 7/10/2025 by MarketBeat.com Staff From Our PartnersI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored"I'm risking my reputation on this"I've stayed quiet for too long, but after everything I've uncovered about what's brewing in the 2025 crypto ma...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Erasca, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Erasca With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
